---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-187702"
form_type: "8-K"
ticker: "JANX"
cik: "0001817713"
company_name: "Janux Therapeutics, Inc."
filed_at: "2023-07-17T23:59:59+00:00"
generated_at: "2026-06-13T07:51:20.099182+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Janux reports ~$304M cash; JANX007 interim data show PSA drops 31-67% in 4/5 patients

## Summary
- Preliminary cash, equivalents, and short-term investments ~$304.1M as of June 30, 2023.
- JANX007 Phase 1a: 4 of 5 patients at flat doses (100-300µg) achieved PSA reductions of 31-67%.
- No dose-limiting toxicities; CRS Grade 1-2 only in patients with PSA reductions; no Grade 3 CRS.
- PK shows prolonged TRACTr exposure and lack of TCE accumulation, consistent with tumor activation.
- Development moving into step-dosing and dose optimization to enhance efficacy with manageable safety.

## SEC filing metadata
- accession: 0001193125-23-187702
- form_type: 8-K
- ticker: JANX
- cik: 0001817713
- company_name: Janux Therapeutics, Inc.
- filed_at: 2023-07-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817713/000119312523187702/0001193125-23-187702-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817713/000119312523187702/d526906d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-187702
- JSON: https://secwatch.observer/filing/0001193125-23-187702.json
- Plain text: https://secwatch.observer/filing/0001193125-23-187702.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.